AstraZeneca Pharma India Balance Sheet Health
Financial Health criteria checks 6/6
AstraZeneca Pharma India has a total shareholder equity of ₹6.8B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹12.4B and ₹5.6B respectively. AstraZeneca Pharma India's EBIT is ₹1.4B making its interest coverage ratio -4.3. It has cash and short-term investments of ₹5.0B.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | -4.3x |
| Cash | ₹4.97b |
| Equity | ₹6.79b |
| Total liabilities | ₹5.62b |
| Total assets | ₹12.41b |
Recent financial health updates
No updates
Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Financial Position Analysis
Short Term Liabilities: ASTRAZEN's short term assets (₹10.7B) exceed its short term liabilities (₹4.7B).
Long Term Liabilities: ASTRAZEN's short term assets (₹10.7B) exceed its long term liabilities (₹871.2M).
Debt to Equity History and Analysis
Debt Level: ASTRAZEN is debt free.
Reducing Debt: ASTRAZEN had no debt 5 years ago.
Debt Coverage: ASTRAZEN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ASTRAZEN has no debt, therefore coverage of interest payments is not a concern.